The development of biologic drugs continues to increase at a rapid pace. Growing numbers of conventional recombinant proteins and monoclonal antibodies, as well as next-generation molecules such as multispecifics, antibody-drug conjugates, and cell and gene therapies, are advancing through the clinic. Many of the biopharma companies behind these drugs are seeking assistance with bioprocess development from outsourcing partners with platform solutions and specialized knowledge, expertise, and technologies.
READ MORE >>
June 2, 2022